1
|
Kosse LJ, Weits G, Vonkeman HE, Tas SW, Hoentjen F, Van Doorn MB, Spuls PI, D'Haens GR, Nurmohamed MT, van Puijenbroek EP, Van Den Bemt BJ, Jessurun NT. Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opin Drug Saf 2021; 20:1565-1572. [PMID: 34348543 DOI: 10.1080/14740338.2021.1963436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Patient-reported outcomes (PROs) on adverse drug reactions (ADRs) are increasingly used in cohort event monitoring (CEM) to obtain a better understanding of patients' real-world experience with drugs. Despite the leading role for patients, little is known about their perspectives on CEM systems. RESEARCH DESIGN AND METHODS In a cross-sectional open survey following the rationale of the Technology Acceptance Model, we aimed to obtain insight in patients' perspectives on the perceived usefulness, ease of use and attitude toward using a PRO-based drug safety monitoring system for ADRs attributed to biologics. RESULTS Patients considered structural reporting of ADRs in web-based questionnaires as useful and not burdensome. It was preferred to link the questionnaire frequency to regular hospital consultations or the biologic administration schedule. Various respondents were interested in sharing questionnaires with their medical specialist (49.0%) or pharmacist (34.2%), and suggested to minimize the questionnaire frequency in case of an unaltered situation or absence of ADRs. CONCLUSIONS Patients' perspectives should be considered in the setup of PRO-based CEM studies, as this contributes to data quality and patient centeredness. Since incorporation of patients' perspectives in CEM studies is indispensable, a delicate balance should be found between user-friendliness and study aims.
Collapse
Affiliation(s)
- Leanne J Kosse
- Netherlands Pharmacovigilance Centre Lareb, 's-hertogenbosch, The Netherlands
| | - Gerda Weits
- Netherlands Pharmacovigilance Centre Lareb, 's-hertogenbosch, The Netherlands
| | - Harald E Vonkeman
- Department of Rheumatology, Medisch Spectrum Twente, Enschede, The Netherlands.,Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands
| | - Sander W Tas
- Department of Rheumatology & Clinical Immunology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam, The Netherlands
| | - Frank Hoentjen
- Department of Gastroenterology, Radboudumc, Nijmegen, The Netherlands
| | | | - Phyllis I Spuls
- Department of Dermatology, Amsterdam UMC, Amsterdam Public Health, Immunity and Infections, University of Amsterdam, Amsterdam, The Netherlands
| | - Geert R D'Haens
- Department of Gastroenterology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Michael T Nurmohamed
- Department of Rheumatology, Reade and Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam, The Netherlands
| | - Eugène P van Puijenbroek
- Netherlands Pharmacovigilance Centre Lareb, 's-hertogenbosch, The Netherlands.,University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology & Pharmacoeconomics, Groningen, The Netherlands
| | - Bart Jf Van Den Bemt
- Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands.,Department of Pharmacy, Radboudumc, Nijmegen, The Netherlands
| | - Naomi T Jessurun
- Netherlands Pharmacovigilance Centre Lareb, 's-hertogenbosch, The Netherlands
| |
Collapse
|